Resources
Resources
CODING & DOCUMENTATION
EDUCATION & EVENTS
ENROLLMENT & CREDENTIALING
FORMS & MANUALS
HEALTHCARE INFORMATION & TECHNOLOGY
PATIENT HEALTH
PHARMACY
POLICIES & GUIDELINES
PRE-SERVICE REVIEW
PROGRAMS & INITIATIVES
PROVIDER NETWORKS & SPECIALTIES
COVID-19 Vaccine Codes - April 18, 2023 FDA Updates
Back to COVID-19 Vaccines page
COVID-19 Vaccine Code Updates
On April 18, 2023, the U.S. Food and Drug Administration (FDA) updated its recommendations for COVID-19 vaccines, authorizing the current bivalent vaccines (original and omicron BA.4/BA.5 strains) to be used for ALL doses administered to individuals 6 months of age and older, including additional doses for certain populations.
| Bivalent Vaccine CPT Code | Vaccine Name | Vaccine Administration Codes |
|---|---|---|
| 91312: Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use | Pfizer COVID-19 Bivalent Vaccine (Ages 12 years and older) |
0121A: First Dose 0124A: Additional Dose |
| 91313: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use | Moderna COVID-19 Bivalent Vaccine (Ages 12 years and older) | 0134A: Additional Dose |
| 91314: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use | Moderna COVID-19 Bivalent Vaccine (Ages 6 months through 11 years) |
0141A: First Dose 0142A: Second Dose 0144A: Additional Dose |
| 91315: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use | Pfizer COVID-19 Bivalent Vaccine (Ages 5 through 11 years) |
0154A: First Dose 0154A: Single Dose |
| 91316: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use | Moderna COVID-19 Bivalent Vaccine (Ages 6 months through 5 years) | 0164A: Additional Dose |
| 91317: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use | Pfizer COVID-19 Bivalent Vaccine (Ages 6 months through 4 years) |
0171A: First Dose 0172A: Second Dose 0173A: Third Dose 0174A: Additional Dose |
Effective April 18, 2023, the FDA EUA update rescinded use of the following monovalent vaccines:
| Monovalent Vaccine CPT Code | Vaccine Name | Vaccine Administration Codesthe |
|---|---|---|
| 91300: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use | Pfizer-BioNTech COVID-19 Vaccine (Ages 12 years and older) |
0001A: First Dose |
| 91301: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use | Moderna COVID-19 Vaccine (Ages 12 years and older) |
0011A: First Dose |
| 91303: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, for intramuscular use | Janssen COVID-19 Vaccine (Ages 18 years and older) |
0031A: Single Dose |
| 91304: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use | Novavax COVID-19 Vaccine, Adjuvanted (Ages 12 years and older) |
0041A: First Dose |
| 91305: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use | Pfizer COVID-19 Vaccine (Ages 12 years and older) |
0051A: First Dose |
| 91306: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use | Moderna COVID-19 Vaccine (Low Dose) |
0064A: Booster Dose |
| 91307: Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use | Pfizer-BioNTech COVID-19 Pediatric Vaccine (Ages 5 through 11 years) |
0071A: First Dose |
| 91308: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use | Pfizer COVID-19 Vaccine (Ages 6 months through 4 years) |
0081A: First Dose |
| 91309: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use | Moderna COVID-19 Vaccine (Ages 6 through 11 years) |
0091A: First Dose |
| 91311: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use | Moderna COVID-19 Pediatric Vaccine (Ages 6 months through 5 years) |
0111A: First Dose |